XLRN - Better Buy: Geron vs. Acceleron
Investing in biotech can be volatile during "normal" market conditions. Today's COVID-19 impacted economy amplifies that volatility and in the process, it's making good companies substantially cheaper than a few months ago. Here two biotechs, one large and one small, battle it out to win investors' hearts as they try to develop drugs for hematologic diseases and more.
Image Source: Getty Images.
The stock of Acceleron Pharma (NASDAQ: XLRN) gained 20% last year only to spike another 55% since the start of 2020. What's driving the stock appreciation? Acceleron and its partner Bristol Myers Squibb (NYSE: BMY) received Food and Drug Administration (FDA) approval last November for Reblozyl to treat anemia in patients with the rare disease beta thalassemia who require regular red blood cell transfusions.